X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (170) 170
Conference Proceeding (52) 52
Publication (15) 15
Book Review (9) 9
Book Chapter (4) 4
Patent (4) 4
Reference (2) 2
Dissertation (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (94) 94
index medicus (50) 50
humans (46) 46
female (28) 28
cancer (23) 23
male (22) 22
middle aged (22) 22
pancreatic cancer (20) 20
aged (18) 18
adult (15) 15
chemotherapy (15) 15
gemcitabine (15) 15
article (14) 14
treatment outcome (14) 14
care and treatment (13) 13
animals (12) 12
metastasis (11) 11
medicine & public health (10) 10
neoplasms - drug therapy (10) 10
pancreatic neoplasms - drug therapy (10) 10
pharmacology & pharmacy (10) 10
apoptosis (9) 9
clinical trials (9) 9
drug therapy (9) 9
mutation (9) 9
pancreatic neoplasms - pathology (9) 9
patients (9) 9
tumors (9) 9
cancer research (8) 8
drug administration schedule (8) 8
drug resistance, neoplasm (8) 8
maximum tolerated dose (8) 8
survival (8) 8
aged, 80 and over (7) 7
antineoplastic agents - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
cancer therapies (7) 7
mice (7) 7
neoplasms - pathology (7) 7
pancreatic neoplasms - genetics (7) 7
pharmacology/toxicology (7) 7
research (7) 7
abridged index medicus (6) 6
adenocarcinoma (6) 6
adenocarcinoma - drug therapy (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
biomarkers (6) 6
colorectal cancer (6) 6
colorectal-cancer (6) 6
dose-response relationship, drug (6) 6
expression (6) 6
health aspects (6) 6
medical research (6) 6
prognosis (6) 6
solid tumors (6) 6
5-fluorouracil (5) 5
antineoplastic agents - pharmacokinetics (5) 5
antineoplastic agents - pharmacology (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
cell biology (5) 5
cells (5) 5
clinical trial (5) 5
dna damage (5) 5
original (5) 5
precision medicine (5) 5
trial (5) 5
veliparib (5) 5
activation (4) 4
adenocarcinoma - genetics (4) 4
adenocarcinoma - pathology (4) 4
analysis (4) 4
antineoplastic agents - administration & dosage (4) 4
beta catenin (4) 4
biopsy (4) 4
breast-cancer (4) 4
carcinoma, pancreatic ductal - genetics (4) 4
carcinoma, pancreatic ductal - pathology (4) 4
cell lung-cancer (4) 4
cell proliferation (4) 4
colon-cancer (4) 4
combination (4) 4
deoxyribonucleic acid--dna (4) 4
dna repair (4) 4
inhibition (4) 4
lapatinib (4) 4
medicine, experimental (4) 4
neoplasm staging (4) 4
pharmacokinetics (4) 4
pharmacology (4) 4
phase i (4) 4
phosphorylation (4) 4
poly polymerase (4) 4
radiotherapy (4) 4
repair (4) 4
review (4) 4
safety (4) 4
signal transduction - drug effects (4) 4
survival rate (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Drug Targets, ISSN 1389-4501, 2014, Volume 15, Issue 1, pp. 17 - 31
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6612 - 6612
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 9, pp. 2488 - 2499
Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet... 
SURVIVAL | PALBOCICLIB | ACTIVATION | ONCOLOGY | PHOSPHORYLATION | SENSITIVITY | LETROZOLE | CELL-CULTURE | COMBINATION | PROTEIN-KINASE B | PACLITAXEL | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Apoptosis - drug effects | Cyclin-Dependent Kinase 4 - genetics | Humans | Indazoles - administration & dosage | Purines - administration & dosage | MCF-7 Cells | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Aminopyridines - administration & dosage | Pyridines - administration & dosage | Receptors, Estrogen - genetics | Pyrimidines - administration & dosage | Cyclin-Dependent Kinase 6 - genetics | Protein-Serine-Threonine Kinases - genetics | Receptors, Estrogen - antagonists & inhibitors | Breast Neoplasms - drug therapy | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Cell Proliferation - drug effects | Mice | Drug Resistance, Neoplasm - drug effects | Senescence | Estrogens | Estrogen receptors | AKT protein | Kinases | Cyclin-dependent kinase 4 | Signal transduction | Xenografts | Inhibition | RNA-mediated interference | Cyclin-dependent kinases | Breast cancer | Pharmacology | siRNA | Tumor cell lines | Ribonucleic acid--RNA | Cyclins | 1-Phosphatidylinositol 3-kinase | Cyclin-dependent kinase 2 | Signaling | Sensitivity | Inhibitors | Protein kinase | Cell lines | Breast | Cancer | Apoptosis | Index Medicus | ER+ breast cancer | RNAi screen | CDK4 | cell cycle | PDK1
Journal Article
Clinical Colorectal Cancer, ISSN 1533-0028, 2016, Volume 15, Issue 4, pp. 345 - 351
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2018, Volume 24, Issue 8, pp. 1816 - 1823
Purpose: Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137. In this first-in-human, phase I, open-label,... 
STIMULATION | ONCOLOGY | IMMUNOTHERAPY | CLINICAL-TRIALS | 4-1BB | LYMPHOMA | MERKEL-CELL-CARCINOMA | CD137 | LEUKEMIA | LIGAND | DESIGNS | Appetite | Slopes | Pharmacodynamics | CD137 antigen | Toxicity | Exanthema | Fatigue | Pharmacology | Patients | Fever | Anticancer properties | Experimental design | Safety engineering | Design standards | Transaminases | Monoclonal antibodies | Biomarkers | Antitumor activity | Bioindicators | Safety | Solid tumors | Pharmacokinetics | Tumors | Cancer
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 09/2017, Volume 77, Issue 18, pp. 5011 - 5025
The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show... 
WIDE IDENTIFICATION | ONCOLOGY | PLATINUM RESISTANCE | POLY(ADP-RIBOSE) GLYCOHYDROLASE | BCR-ABL | NUCLEAR EXPORT | S-PHASE | BINDING PROTEIN HUR | BRCA2 | TUMORS | PANCREATIC-CANCER CELLS | Up-Regulation | Cell Proliferation | Pancreatic Neoplasms - metabolism | Glycoside Hydrolases - genetics | Humans | Carcinoma, Pancreatic Ductal - metabolism | DNA Repair - genetics | Carcinoma, Pancreatic Ductal - genetics | ELAV-Like Protein 1 - metabolism | Biomarkers, Tumor - metabolism | DNA Damage - genetics | Female | Tumor Cells, Cultured | Poly(ADP-ribose) Polymerases - chemistry | DNA Damage - drug effects | DNA Repair - drug effects | RNA Processing, Post-Transcriptional | Pancreatic Neoplasms - pathology | RNA, Messenger - genetics | ELAV-Like Protein 1 - genetics | Pancreatic Neoplasms - genetics | ELAV-Like Protein 1 - antagonists & inhibitors | Carcinoma, Pancreatic Ductal - pathology | Xenograft Model Antitumor Assays | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Cell Nucleus - genetics | Mice, Nude | Biomarkers, Tumor - genetics | Mice | Cell Nucleus - drug effects | Apoptosis | Post-transcription | Chromatin | Immunoprecipitation | DNA polymerase | DNA damage | ADP | DNA repair | Proteins | Ribose | Xenografts | PARP-1 protein | Pancreas | Repair | Damage accumulation | Deoxyribonucleic acid--DNA | HuR protein | Translocation | CRISPR | Stability | Poly(ADP-ribose) polymerase | Gene expression | Poly(ADP-ribose) Polymerase 1 | Inhibitors | Nuclei (cytology) | Solid tumors | Cytoplasm | Tumors | Cancer | mRNA stability | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 25, pp. 2417 - 2428
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 09/2016, Volume 6, Issue 1, pp. 33323 - 33323
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 3618 - 3618
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 4074 - 4074
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 07/2019, Volume 121, Issue 3, pp. 264 - 270
BACKGROUND: Molecular profiling is increasingly used to match patients with metastatic cancer to targeted therapies, but obtaining a high-quality biopsy... 
BREAST-CANCER | HETEROGENEITY | BIOMARKERS | EVOLUTION | ONCOLOGY | COLORECTAL-CANCER | PATTERNS | GEMCITABINE | Adenocarcinoma | Profiling | Statistical analysis | Lung | Statistical methods | Metastasis | Myc protein | Metastases | Biopsy | ERCC1 protein | Sampling methods | Mutation | Lesions | Pancreas | Tumors | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e18100 - e18100
Journal Article
Journal Article